Investigating a new treatment for alcohol use disorder using a specific medication
Selective Glucocorticoid Receptor Antagonism in Alcohol Use Disorder: A Human Neuroscience Study
['FUNDING_R01'] · UNIVERSITY OF KENTUCKY · NIH-10801394
This study is looking at how a medication called PT150 might help people with alcohol use disorder by seeing how it affects their cravings and reactions to stress, and it's designed for individuals who are trying to manage their alcohol use.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF KENTUCKY (nih funded) |
| Locations | 1 site (LEXINGTON, UNITED STATES) |
| Trial ID | NIH-10801394 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how a selective glucocorticoid receptor antagonist, PT150, can help individuals with alcohol use disorder (AUD). Participants will undergo a series of experimental sessions where they will be given different doses of PT150 after a maintenance period. The study will assess their responses to stress and alcohol consumption, measuring various behavioral and physiological factors. By translating findings from animal studies to humans, the research aims to explore the potential of this medication in reducing cravings and withdrawal symptoms associated with AUD.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with alcohol use disorder who are seeking treatment options.
Not a fit: Patients who do not have alcohol use disorder or those who are not willing to participate in experimental sessions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that effectively reduces cravings and withdrawal symptoms in individuals with alcohol use disorder.
How similar studies have performed: Previous preclinical studies have shown promising results with glucocorticoid receptor antagonists in reducing alcohol-related behaviors, but this approach is relatively novel in human subjects.
Where this research is happening
LEXINGTON, UNITED STATES
- UNIVERSITY OF KENTUCKY — LEXINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FILLMORE, MARK T — UNIVERSITY OF KENTUCKY
- Study coordinator: FILLMORE, MARK T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alcohol withdrawal syndrome